Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + docetaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- STADA
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
EPI-cell is a neoadjuvant chemotherapy regimen evaluated for the treatment of primary breast cancer, specifically investigated by Asklepios Krankenhaus Weißenfels. The regimen consists of a sequential administration schedule: three cycles of epirubicin and docetaxel followed by three cycles of carboplatin and docetaxel. Epirubicin is an anthracycline that acts by intercalating into DNA and inhibiting topoisomerase II, thereby preventing DNA replication and inducing apoptosis. Docetaxel is a taxane that stabilizes microtubules, leading to cell cycle arrest. Carboplatin is a platinum-based alkylating agent that forms covalent DNA cross-links, interfering with DNA repair and synthesis. The EPI-cell study (Phase 2) was designed to assess the pathological complete response (pCR) and the feasibility of breast-conserving surgery in patients with primary breast cancer.
- Other names
- EPI-cell regimenEpirubicin/Docetaxel followed by Carboplatin/Docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on epirubicin + docetaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + docetaxel + carboplatin.